

Online Appendix 2 -- Reviewer Relationships With Industry and Other Entities (Comprehensive)—2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants

Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Timothy A. Dewhurst	Official Reviewer— Board of Governors	Kaiser Permanente, Washington—Seattle Cardiology Operations Chief	None	None	None	None	<ul style="list-style-type: none"> • Biotronik • Group Health Permanente* • Ratchet Health* 	None
Joseph E. Marine	Official Reviewer— ACC Task Force on Clinical Expert Consensus Decision Pathways	Johns Hopkins University School of Medicine— Associate Professor of Medicine	None	None	None	None	<ul style="list-style-type: none"> • UpToDate 	None
Linda A. Briggs	Organizational Reviewer—AANP	The George Washington University School of Nursing—Assistant Professor	None	None	None	None	None	None
Mark A. Crowther	Organizational Reviewer— Anticoagulation Forum	McMaster University— Chair of Department of Medicine	<ul style="list-style-type: none"> • Portola† • Shionogi Pharma 	<ul style="list-style-type: none"> • Alexion† • Bayer HealthCare Pharmaceuticals • Boehringer Ingelheim • Pfizer Canada† 	None	<ul style="list-style-type: none"> • Bayer Healthcare Pharmaceuticals (DSMB) • Daiichi Sankyo (DSMB) 	<ul style="list-style-type: none"> • Bayer* • Leo Pharma* 	None
Eileen Mary Handberg	Organizational Reviewer—ACC and PCNA	University of Florida— Research Professor of Medicine; Director, Clinical Trials Program; Florida CARES & CAP— Program Director	None	None	None	None	<ul style="list-style-type: none"> • Amarin† • Amgen • AstraZeneca† • Boehringer Ingelheim† • Daiichi Sankyo† 	None
Jeffrey Kline	Organizational Reviewer—SAEM	Indiana University School of Medicine—Vice Chair of Research, Department of Emergency Medicine; Professor, Department of Cellular and Integrative Physiology	None	None	None	<ul style="list-style-type: none"> • Ikaria† • NIH† 	<ul style="list-style-type: none"> • Gilead Sciences* • Stago 	None
Geno J. Merli	Organizational Reviewer—ACP	Thomas Jefferson University Hospital—	None	None	None	<ul style="list-style-type: none"> • Bristol-Myers Squibb 	None	None

Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Leadership Council	Cardiology Department; Vice Director						
Christopher B. Granger	Content Reviewer— ACC Roundtable Participant	Duke Clinical Research Institute—Professor of Medicine; Director, Cardiac Care Unit	<ul style="list-style-type: none"> • AbbVie • Armetheon† • AstraZeneca† • Bayer† • Boehringer Ingelheim† • Boston Scientific • Bristol-Myers Squibb† • Daiichi Sankyo† • Eli Lilly† • Gilead Sciences† • GlaxoSmithKline † • Hoffman LaRoche† • Janssen† • Medtronic† • NIH† • Novartis† • Pfizer† • Sirtex† • The Medicines Company† • Verseon† 	None	None	<ul style="list-style-type: none"> • Armetheon† • AstraZeneca† • Bayer† • Boehringer Ingelheim† • Bristol-Myers Squibb† • Daiichi Sankyo† • FDA† • GlaxoSmithKline† • Janssen† • Medtronic Foundation† • Novartis† • Pfizer • The Medicines Company† 	<ul style="list-style-type: none"> • GE† • Medtronic† • Philips† • Spacelabs Healthcare† • ZOLL† 	None
Kousik Krishnan	Content Reviewer— EP Section Leadership Council	Rush University Medical Center—Associate Professor of Medicine & Pediatrics; Director, Clinical Cardiac Electrophysiology Fellowship Program; Director, Arrhythmia Device Clinic; Associate Director, Electrophysiology Lab	<ul style="list-style-type: none"> • Bristol-Myers Squibb • Janssen • Pfizer • ZOLL 	None	None	None	<ul style="list-style-type: none"> • Boston Scientific† • Medtronic† • St. Jude Medical† 	None
Pamela B. Morris	Content Reviewer—	Medical University of	<ul style="list-style-type: none"> • Amgen 	None	None	<ul style="list-style-type: none"> • Amgen 	None	None

Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Task Force on Expert Consensus Decision Pathways	South Carolina—Director, Seinsheimer Cardiovascular Health Program; Co-Director, Women's Heart Care	<ul style="list-style-type: none"> • AstraZeneca • Sanofi Regeneron 					
Win-Kuang Shen	Content Reviewer— Individual	Mayo Clinic Arizona - Phoenix Campus— Professor of Medicine; Consultant	None	None	None	None	None	None
Sarah A. Spinler	Content Reviewer— ACC Roundtable Participant	University of the Sciences Philadelphia College of Pharmacy—Professor of Clinical Pharmacy	<ul style="list-style-type: none"> • Boehringer Ingelheim 	<ul style="list-style-type: none"> • Bristol-Myers Squibb 	None	None	None	None
Karol E. Watson	Content Reviewer— Task Force on Expert Consensus Decision Pathways	UCLA Medical School— Co-Director, UCLA Program in Preventive Cardiology	<ul style="list-style-type: none"> • Amgen* • AstraZeneca • Boehringer Ingelheim† • Daiichi Sanko • GlaxoSmithKline 	None	None	<ul style="list-style-type: none"> • Merck (DSMB) 	<ul style="list-style-type: none"> • Quest† 	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees.

* No financial benefit.

† Significant relationship.

AANP=American Association of Nurse Practitioners; ACC=American College of Cardiology; ACCP=American College of Clinical Pharmacy; ACP=American College of Physicians; CCEP=Clinical Cardiac Electrophysiology; DSMB=Data Safety Monitoring Board; EP=Electrophysiology; HRS=Heart Rhythm Society; NIH=National Institutes of Health; PCNA=Preventative Cardiovascular Nurses Association; SAEM=Society for Academic Emergency Medicine; UCLA=University of Southern California at Los Angeles.